Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

TWEAK/Fn14 Activation Participates in Skin Inflammation.

Liu Q, Xiao S, Xia Y.

Mediators Inflamm. 2017;2017:6746870. doi: 10.1155/2017/6746870. Epub 2017 Sep 6. Review.

2.

Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, Moreno-Aliaga MJ, Portillo MP.

Int J Mol Sci. 2017 Aug 15;18(8). pii: E1770. doi: 10.3390/ijms18081770. Review.

3.

The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors.

Liu H, Lin D, Xiang H, Chen W, Zhao S, Peng H, Yang J, Chen P, Chen S, Lu H.

Exp Ther Med. 2017 Aug;14(2):891-897. doi: 10.3892/etm.2017.4600. Epub 2017 Jun 14.

4.

Lipopolysaccharide Upregulated Intestinal Epithelial Cell Expression of Fn14 and Activation of Fn14 Signaling Amplify Intestinal TLR4-Mediated Inflammation.

Qi X, Qin L, Du R, Chen Y, Lei M, Deng M, Wang J.

Front Cell Infect Microbiol. 2017 Jul 11;7:315. doi: 10.3389/fcimb.2017.00315. eCollection 2017.

5.

Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions.

Alvarado-Vazquez PA, Bernal L, Paige CA, Grosick RL, Moracho Vilrriales C, Ferreira DW, Ulecia-Morón C, Romero-Sandoval EA.

Immunobiology. 2017 Aug;222(8-9):900-912. doi: 10.1016/j.imbio.2017.05.011. Epub 2017 May 16.

PMID:
28545809
6.

Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.

Roos A, Dhruv HD, Mathews IT, Inge LJ, Tuncali S, Hartman LK, Chow D, Millard N, Yin HH, Kloss J, Loftus JC, Winkles JA, Berens ME, Tran NL.

Oncotarget. 2017 Feb 14;8(7):12234-12246. doi: 10.18632/oncotarget.14685.

7.

TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB.

Hénaut L, Sanz AB, Martin-Sanchez D, Carrasco S, Villa-Bellosta R, Aldamiz-Echevarria G, Massy ZA, Sanchez-Nino MD, Ortiz A.

Cell Death Dis. 2016 Jul 21;7:e2305. doi: 10.1038/cddis.2016.220.

8.

Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease.

Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, O'Neil SP, Zhan Y, Brenneman K, Homer B, Neubert H, Karim R, Pullen N, Evans SM, Fleming M, Chockalingam P, Lin LL.

PLoS One. 2016 May 12;11(5):e0155368. doi: 10.1371/journal.pone.0155368. eCollection 2016.

9.

Heightened TWEAK-NF-κB signaling and inflammation-associated fibrosis in paralyzed muscles of men with chronic spinal cord injury.

Yarar-Fisher C, Bickel CS, Kelly NA, Stec MJ, Windham ST, McLain AB, Oster RA, Bamman MM.

Am J Physiol Endocrinol Metab. 2016 May 1;310(9):E754-61. doi: 10.1152/ajpendo.00240.2015. Epub 2016 Mar 1.

10.

The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease.

Mustafa S, Martin HL, Burkly L, Costa A, Martins ML, Schwaninger M, Teismann P.

Neuroscience. 2016 Apr 5;319:116-22. doi: 10.1016/j.neuroscience.2016.01.034. Epub 2016 Jan 22.

11.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

12.

CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury.

Akahori H, Karmali V, Polavarapu R, Lyle AN, Weiss D, Shin E, Husain A, Naqvi N, Van Dam R, Habib A, Choi CU, King AL, Pachura K, Taylor WR, Lefer DJ, Finn AV.

Nat Commun. 2015 Aug 5;6:7792. doi: 10.1038/ncomms8792.

13.

Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.

Cheng Q, Inaba Y, Lu P, Xu M, He J, Zhao Y, Guo GL, Kuruba R, de la Vega R, Evans RW, Li S, Xie W.

Mol Endocrinol. 2015 Apr;29(4):571-82. doi: 10.1210/me.2014-1337. Epub 2015 Feb 26.

14.

TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation.

Raue U, Jemiolo B, Yang Y, Trappe S.

J Appl Physiol (1985). 2015 Mar 1;118(5):569-78. doi: 10.1152/japplphysiol.00759.2014. Epub 2014 Dec 24.

15.

Proteolytic activation of the protease-activated receptor (PAR)-2 by the glycosylphosphatidylinositol-anchored serine protease testisin.

Driesbaugh KH, Buzza MS, Martin EW, Conway GD, Kao JP, Antalis TM.

J Biol Chem. 2015 Feb 6;290(6):3529-41. doi: 10.1074/jbc.M114.628560. Epub 2014 Dec 17.

16.

TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.

Yadava RS, Foff EP, Yu Q, Gladman JT, Kim YK, Bhatt KS, Thornton CA, Zheng TS, Mahadevan MS.

Hum Mol Genet. 2015 Apr 1;24(7):2035-48. doi: 10.1093/hmg/ddu617. Epub 2014 Dec 11.

17.

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H.

Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014.

18.

TWEAK and LTβ Signaling during Chronic Liver Disease.

Dwyer BJ, Olynyk JK, Ramm GA, Tirnitz-Parker JE.

Front Immunol. 2014 Feb 13;5:39. doi: 10.3389/fimmu.2014.00039. eCollection 2014. Review.

19.

Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis.

Enwere EK, Lacasse EC, Adam NJ, Korneluk RG.

Front Immunol. 2014 Feb 5;5:34. doi: 10.3389/fimmu.2014.00034. eCollection 2014. Review.

20.

TWEAK and the progression of renal disease: clinical translation.

Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A.

Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i54-i62. doi: 10.1093/ndt/gft342. Review.

Supplemental Content

Support Center